Pfizer Drug Wins U.K. Support Following Overhaul of Cancer Fund
- Bosulif recommended for NHS use in treating leukemia patients
- Drug costs $58,000 a year before discounts from Pfizer
This article is for subscribers only.
Pfizer Inc.’s leukemia drug Bosulif won the backing of a key health authority in the U.K. after the nation’s public health system overhauled how it pays for cancer treatments and the pharmaceutical company offered discounts.
The U.S. drugmaker is providing undisclosed concessions on the current price of 45,000 pounds ($58,000) a year for treating each patient, the National Institute for Health and Care Excellence said Thursday in a statement. NICE, which assesses the cost and effectiveness of medicines, said it would recommend that the U.K.’s National Health Service begin using the drug for people with chronic myeloid leukemia.